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ABSTRACT
Aim: To examine the effect of apolipoprotein E (APOE) and APOE promoter 
polymorphisms on the occurrence of Alzheimer-type pathology within the cerebral 
cortex of very elderly individuals, and the effect of APOE polymorphism on the 
prevalence and incidence of dementia and neuropathologically defined Alzheimer’s 
disease (AD) in these individuals. 
Materials and methods: This study is based on neuropathological findings of 281 
autopsied individuals aged 85 years or more, who lived in the city of Vantaa on the 1st
of April, 1991, were clinically examined for the presence of dementia, genotyped for 
the apoE gene and its promoter, and died by the 31st of March 2001. Three silver 
staining methods (Methenamine silver, Bielschowsky and Gallyas) were used to 
estimate the cortical ?-amyloid peptide (A?) load, measure the cortical neurofibrillary 
tangle (NFT) count, and define the CERAD score for neuritic plaques and the Braak 
stage of cortical neurofibrillary pathology. These neuropathological findings were 
correlated with the cognitive status and apoE and apoE promoter genotypes of these 
individuals. The CERAD score for neuritic plaques and the Braak stage of the cortical 
neurofibrillary pathology were used to define the neuropathological AD. 
Results: Polymorphism in APOE had a significant effect on cortical A?-load both in 
demented and non-demented individuals, with allele ?4 increasing and ?2 decreasing 
the A? load. The APOE ?4 allele was also associated with increased density of 
neocortical NFTs. Furthermore, the prevalence of dementia, and particularly the 
prevalence of neuropathological AD was associated with the apoE genotype. 
However, the apoE genotype did not appear to have an effect on the incidence of 
dementia in this age group. In contrast, there was an association between the APOE ?4
allele and neuropathologically defined AD even in a non-demented subpopulation. 
Some AD-type neuropathological changes were present in almost all individuals. The 
APOE promoter polymorphism had an effect on the AD-type neuropathological 
changes in individuals with the apoE genotype ?3/?3.
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Conclusion: APOE polymorphism has an effect on the prevalence of dementia, and 
particularly on the Alzheimer-type neuropathological changes even in these very 
elderly individuals. The APOE promoter polymorphism seems to have a weaker effect  
on the extent of Alzheimer-type neuropathological changes. All individuals may have  
a potential to develop AD, but the timing of this process seems to be strongly affected  
by the apoE genotype. 
 8
1 Introduction 
Research on Alzheimer’s disease (AD) has become increasingly popular after the 
biochemical  and genetic background of its main pathological hallmarks, senile 
plaques and neurofibrillary tangles, were clarified (Glenner et al, 1984; Masters et al, 
1985; Delacourte et al, 1986; Neve et al, 1986; Kang et al, 1987; Wischik et al, 1988). 
Methodological improvements, particularly in genetics, have made it possible to use 
transgenic animals and cell cultures in research on AD. This has resulted in an 
exhaustive increase in the number of publications and in detailed descriptions of the 
biochemical events possibly leading to formation of AD-type pathological changes. 
Some improvements have also been made in helping people, who suffer the 
symptoms of AD. 
 However, a few crucial questions remain unresolved. First: Although it has 
been proven that abnormal structure of the amyloid precursor protein (APP) and 
increased production of its cleavage product amyloid-? peptide (A?) cause AD in 
individuals with genetic abnormalities (Gandy et al, 2000), it is less clear which 
processes underlie the most common form of AD, late-onset AD. Second: Both the 
extent of AD-type changes in the brain and AD are positively correlated with age 
(Katzman et al, 1994; Jorm et al, 1998). Is AD actually the same as brain aging?  
Third: Do the first, minor AD-type pathological changes in the human brain 
inevitably progress towards full AD-type pathology, or could they remain as they are, 
or even disappear?  
These aspects will be discussed in the context of the results of this population-
based study of AD-type cerebral changes in individuals aged 85 years or more. 
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2 Review of the literature 
2.1. Alzheimer's disease 
2.1.1. Clinical presentation 
Gradual, progressive decline in cognitive functions is the most typical manifestation 
of Alzheimer's disease (AD) (Stern et al, 1987; Thal et al, 1988). It is suggested that 
lowered cognitive performance in abstract reasoning and retention of verbal material 
may be the first sign of AD (Elias et al, 2000), although memory impairment is likely 
to be the first symptom recognized by the patient. Problems with visiospatial learning 
occur also at an early phase of the disease (Blackwell et al, 2003). In spite of the 
memory impairment, personality and social skills are not notably affected at the 
beginning of the disease (Miller et al, 1997). In the late stage of AD, deterioration of 
cognitive functions are often accompanied by loss of mobility and incontinence 
(Bayles et al, 2000). According to an analysis of 100 autopsy-confirmed AD patients, 
the mean duration of the disease from the onset of symptoms until death is about nine 
years, although the range is large (Jost et al, 1995). Duration of the disease obviously 
depends on the timing of the diagnosis, other diseases affecting the patient and/or 
their age.  
The methods used in the clinical and differential diagnosis of AD include: 
A:   Examination of brain function:  
- interview with neurological and neuropsychological examination 
B:   Examination of brain morphology 
- computed tomography (CT) or 
- magnetic resonance imaging (MRI) 
C:   Biochemistry and molecular genetics 
- blood tests to find a possible metabolic disorder or vitamin 
deficiency.  
 10
- analysis of the cerebrospinal fluid; not routine.  
- genetic tests possible if evidence of family history; not routine. 
Interview with neurological and neuropsychological examination  
The cognitive functions measured for the diagnosis of dementia during the 
examination of a patient include memory, executive functions, other higher cortical 
function, behavioural and emotional function, and social function (American 
Psychiatric Association 1987). The duration of the symptoms, evidence for the 
progression of cognitive impairment, normal consciousness, and assumed organic 
cause of the symptoms may also be used as criteria for dementia (American 
Psychiatric Association 1987). It should be noted that different sets of diagnostic 
criteria may result in major differences in the outcome of the examination, i.e. the 
same individual may be considered demented or non-demented depending on the 
criteria used (Erkinjuntti et al, 1997). 
    After the diagnosis has been established, the type of the dementia will be 
defined. A diagnosis of probable AD requires the presence of dementia without any 
other clinically significant causes underlying the symptoms (McKhann et al, 1984). A 
diagnosis of possible AD can be made if the dementia syndrome is not entirely typical 
for AD or there are other disorders sufficient to produce dementia, but these are not 
suggested to be the main cause of the dementia. Definitive diagnosis of AD can be 
made only when neuropathological evidence of AD is also available. 
Computed tomography and magnetic resonance imaging
Computed tomography (CT) and magnetic resonance imaging (MRI) are used for the 
macroscopical evaluation of brain structure. MRI brain images have considerable 
intrinsic contrast sensitivity, clearly visualizing the boundaries between white and 
grey brain matter, in contrast to CT images (Jagust et al, 1991). Thus, although CT 
scans can be used to exclude mass lesions (brain tumours, subdural haematomas), 
MRI is better for detection of white matter lesions and atrophic areas of the brain 
related to specific neurodegenerative diseases. 
    In AD the mesial temporal cortex in particular is atrophic, and this can be 
visualized with MRI (Laakso et al, 1998). Furthermore, in a follow-up study 
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hippocampal volume decline has been correlated with decline in cognitive functions 
even in non-demented individuals (Jack et al, 2000) 
    On the other hand, for example, focal ischemic lesions seen with MRI or CT 
favour the diagnosis of vascular dementia, although these lesions do not exclude the 
possibility of AD or other neurodegenerative disease. 
Blood tests to find the possible metabolic disorder or vitamin deficiency 
Blood tests are used to exclude the possibility of a metabolic disorder or vitamin 
deficiency underlying dementia, and it is important to consider these potentially 
treatable causes of dementia. 
Analysis of the cerebrospinal fluid
Possibly the most promising new tool (if one forgets the problems related with 
obtaining the sample) for the clinical diagnosis of AD is the analysis of cerebrospinal 
fluid (CSF) for biochemical markers of this disease (Bancher et al, 1998). One of 
these biochemical markers is the neurotoxic (Yankner et al, 1989) ?-amyloid peptide 
(A?), which is a cleavage product of a cell membrane protein, amyloid precursor 
protein (APP) (Glenner et al, 1984; Masters et al, 1985; Kang et al, 1987). In 
physiological conditions A? can be detected in two major forms, A?40 and A?42, 
which differ from each other by their length (Haass et al, 1992; Kuo et al, 1996) . 
Both of these peptides are able to aggregate to form a senile plaque, one of the two 
pathological hallmarks of AD, although A?42 is more effective in this (Iwatsubo et al, 
1995). The production of A?42 is increased in genetically modified cells which carry 
a mutation able to cause AD in humans (Citron et al, 1997). However, this increased 
production of A?42 does not affect the concentration of A?42 in the CSF of 
cognitively normal carriers of various mutations predisposing to AD (Almkvist et al, 
2003). It may be that the diffusion of A? from the brain parenchyma to CSF is 
inefficient in these individuals. This  suggestion is supported by the finding that high 
CSF levels of A?42 in non-demented elderly individuals seems to “prevent” dementia 
(Skoog et al, 2003).  
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In normal individuals the CSF concentrations of both types of A? are lower in 
infants than in adults, but from early adulthood the concentration of A?40 tends to 
decrease, while the concentration of A?42 remains stable (Fukuyama et al, 2000). 
However, in CSF the concentration of A?42, and particularly the ratio between A?42 
and A?40, is lower in individuals with AD than in cognitively normal controls 
(Fukuyama et al, 2000; Maruyama et al, 2001). This may not be true in individuals 
with mild cognitive impairment (MCI) who eventually develop AD (Maruyama et al, 
2001). On the other hand, it has also been shown that the level of A?42 decreases 
below the normal level earlier than does the level of A?40 in non-demented elderly 
individuals who eventually develop AD (Skoog et al, 2003).  
The concentration of another biochemical marker, tau protein, which 
participates in the formation and stabilization of microtubules in neurons (Kosik et al, 
1994), is already affected in the MCI phase of AD (Maruyama et al, 2001). Contrary 
to the decreased concentration of A?42, the concentration of tau in CSF increases in 
MCI and AD (Maruyama et al, 2001; Sunderland et al, 2003) . However, because the 
increased concentration of tau is probably just an indicator of neuronal death, it is also 
likely to be associated with various cerebral degenerative processes other than AD. A 
more specific biochemical marker is hyperphosphorylated tau (Hampel et al, 2003), 
which participates in the formation of paired helical filaments (PHF) – the main 
structural component of a neurofibrillary tangle (Kosik et al, 1994), which is the other 
pathological hallmark of AD.       
Genetic tests
Genetic tests are of limited value as diagnostic tools, because causative genetic 
mutations are relatively rare causes of AD (Rocchi et al, 2003). The most common 
form of AD, age-related AD, is multifactorial in nature (Rocchi et al, 2003). In 
familial AD cases genetic tests may confirm the clinical diagnosis. Several ethical 
problems are related with these tests. 
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2.1.2. Neuropathology 
Since the original description of AD (Alzheimer 1907), the presence of senile plaques 
and neurofibrillary tangles are considered to be the hallmarks of AD. 
Senile plaques
Senile plaques are argyrophilic extracellular structures, comprised mainly of A?
(Glenner et al, 1984; Masters et al, 1985). Based on silver staining and other tinctorial 
staining methods, the senile plaques were categorized into three groups: (1) classical 
or mature plaques consist of a dense amyloid core surrounded by a clear halo and 
peripheral aggregations of argyrophilic material; (2) primitive or immature plaques 
are composed of relatively dense argyrophilic material, but do not contain a core; (3) 
burned-out plaques are similar to the dense amyloid core but lack the other features of 
the classical plaques (Wisniewski et al, 1973). However, after it was possible to detect 
A? with immunohistochemical techniques, it became clear that there are also other 
kinds of senile plaques (i.e. A?-positive plaques) (Yamaguchi et al, 1988; Wisniewski 
et al, 1989a). Thus, A? can also form non-fibrillar aggregations, so-called diffuse 
plaques, in which no recognizable neuritic pathology is present (Yamaguchi et al, 
1988). It is suggested that diffuse plaques are antecedents of the primitive plaques 
(Ikeda et al, 1989), and that there is a continuous change from non-fibrillar 
accumulations of A? without any cellular response to clustering of amyloid fibrils 
with large degenerating neurites and intensive astroglial reaction (Yamaguchi et al, 
1991). The neocortical distribution of diffuse plaques does not fully match that of 
neuritic plaques, however, suggesting that the process leading from diffuse deposits to 
fibrillar amyloid deposits accompanied with neuritic pathology depends not only on 
the accumulation but also on the location of A? deposits in the neocortex (Braak et al, 
1989; Delaère et al, 1991). To make the issue of senile plaques even more complex, 
the type of neuritic pathology within the senile plaques may vary from distended 
abnormal neuronal processes filled with APP (Weghe et al, 1991; Yasuhara et al, 
1994) and chromogranin A (Munoz 1991) to elongated tau-positive neurites (Weghe 
et al, 1991; Yasuhara et al, 1994).  
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Accumulation of the longer form of A? (A?42) appears to precede the 
accumulation of the shorter form of A? (A?40), although there is a correlation 
between the levels of insoluble forms of these peptides in the brain (Iwatsubo et al, 
1995; Morishima-Kawashima et al, 2000). According to a large autopsy series, the 
cortical accumulation of A? appears to start at around 40 years of age in some 
individuals (Braak et al, 1997), but aggregations of A? may be detected in much 
younger individuals in special circumstances (Nicoll et al, 1995). These aggregations 
become more common in elderly individuals and after 80 years of age the vast 
majority of individuals show senile plaques (Yamada et al, 1996). 
Neurofibrillary tangles 
Silver-positive neurofibrillary tangles (NFTs), dystrophic neurites and neuropil 
threads are the three main forms of abnormal accumulations of paired helical 
filaments (PHF) seen in AD (Probst et al, 1991). The development of NFT starts with 
the formation of a granular “pre-tangle” in the nerve cell body (Bancher et al, 1989). 
These “pre-tangles” are detectable immunohistochemically with antibodies to 
hyperphosphorylated tau-protein but not with silver stains (Bancher et al, 1989; Braak 
et al, 1994). Normal, dephosphorylated tau-protein participates in the formation and 
stabilisation of intraneuronal microtubules (Kosik et al, 1994). “Pre-tangles” are 
common in elderly individuals with or without AD (Bancher et al, 1989).  
The next step in the development of NFT is the formation of fibrillar bundles 
of PHFs (Kosik et al, 1994). These bundles can be detected with silver stains as 
intraneuronal filamentous structures which eventually increase in number to form a 
classical NFT (Bancher et al, 1989). The first NFTs can be seen in the transentorhinal 
cortex of some non-demented young adults, before there is detectable ?-amyloid 
protein accumulation (Ghebremedehin et al, 1998). A neuron may survive for a long 
period of time with a NFT, although the neuron’s function is not likely to be normal 
(Morsch et al, 1999). When a tangle-bearing neuron dies the NFT may remain as an 
extracellular “ghost-tangle”  (Tolnay et al, 1999), which does not stain with antibodies 
to hyperphosphorylated tau but with silver stains and antibodies to ubiquitin (Bancher 
et al, 1989). 
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Other pathological changes related to AD
In addition to senile plaques and neurofibrillary tangles, other pathological changes 
are related to AD. These include amyloid angiopathy, granulo-vacuolar degeneration, 
Hirano bodies, spongiformic changes, astrocytosis, synapse loss, and loss of neurons 
(Duyckaerts et al, 2003). It has even been suggested that the variation in the clinical 
picture among AD patients may be a result of the mosaic of pathological changes that 
vary from patient to patient in intensity and distribution (Di Patre et al, 1999). 
2.1.3. Neuropathological criteria for AD
The cerebral cortex of non-demented elderly individuals shows a wide range of 
changes typically seen in patients with AD (Hulette et al, 1998; Riley et al, 2002). 
Actually, it may even be difficult to find an elderly person without a senile plaque or 
neurofibrillary tangle (Braak et al, 1997; Davies et al, 1999; Price et al, 1999; 
Knopman et al, 2003). This suggests that the slow process towards clinical AD may 
have started in all or almost all elderly individuals, although the changes may not yet 
be clinically significant in all individuals. On the other hand, there is some evidence 
that even mild AD-type neuropathology may be associated with changes in cognitive 
performance (Morris et al, 1991; Hulette et al, 1998; Riley et al, 2002) in non-
demented individuals, and may be enough to cause dementia in individuals with 
additional pathology (Nagy et al, 1997a; Esiri et al, 1999). Thus, one could assume 
that only the absence of senile plaques and neurofibrillary tangles excludes the 
possibility of clinically significant AD (Morris et al, 1991). However, there is a 
significant correlation between cognitive function and the severity and extent of AD- 
type neuropathological changes (Nagy et al, 1995a; Geddes et al, 1997; Thal et al, 
1998), and thus it is very unlikely that any AD-type change would be clinically 
significant in every individual. Because of this, several attempts to develop 
neuropathological criteria for AD have been made, mainly based on the density of 
senile plaques either with or without considering the presence of neurofibrillary 
tangles. The first consensus criteria for the neuropathological diagnosis of AD was 
mainly based on the density of senile plaques in the neocortex  – neurofibrillary 
tangles were considered only in individuals less than 50 years of age (Khachaturian 
1985). However, after the development of new, sensitive silver and 
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immunohistochemical staining methods it became clear that these criteria were not 
specific enough. The next attempt was made a few years later: 
The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) (Mirra et al, 
1991)
These criteria are based on the maximum density of neuritic plaques in four 
neocortical areas (middle frontal gyrus, superior and middle temporal gyrus, and 
inferior parietal lobule). The scoring is based on the three possible densities of 
neuritic plaques (“sparse”, “moderate” and “frequent”). The possible diagnostic 
categories ? “normal”, “possible AD”, “probable AD” and “definite AD” ? give 
information about the likelihood of AD in an autopsied individual. The cognitive 
status (non-demented vs demented) and age of the patient affect the interpretion: only 
“normal” or “possible AD” diagnoses are available for a non-demented individual, 
while all diagnoses are in use for a demented individual. A lower density of neuritic 
plaques is needed for diagnostic categories of AD in a young individual than in an 
older individual. Three age groups are used: younger than 50 years, 50-75 years and 
over 75 years. One may wonder whether or not the same density of neuritic plaques is 
truly more dangerous to a young brain than it is to an old brain!  
The protocol recommends the use of methods such as modified Bielshowsky 
staining for the detection of neuritic plaques (Mirra et al, 1991). However, although a 
sensitive staining method for senile plaques (Wisniewski et al, 1989b), it is difficult to 
control and gives variable results (Mirra et al, 1994b; Litchfield et al, 2001). Another 
practical problem is related to the definition of the “neuritic plaque”. According to the 
CERAD protocol, this type of senile plaque displays clusters of abnormally distended 
or “dystrophic” neuronal processes or neurites (Mirra et al, 1994a). However, all 
cored senile plaques are surrounded by distended neurites containing chromogranin A, 
and some non-cored senile plaques may contain these structures as well (Munoz 
1991). Distended or globular dystrophic neurites with chromogranin A also contain 
APP but not hyperphosphorylated tau (Weghe et al, 1991; Yasuhara et al, 1994). In 
contrast, elongated or thread-like dystrophic neurites in senile plaques are tau-positive 
(Weghe et al, 1991; Yasuhara et al, 1994). Senile plaques with chromogranin A- and 
APP-positive but tau-negative dystrophic neurites can be seen in non-demented 
elderly individuals, while tau-positive dystrophic neurites are associated with AD and 
 17
are not frequently seen in cognitively normal elderly individuals (Yasuhara et al, 1994; 
Wang et al, 1995; Knopman et al, 2003). Because Bielschowsky staining is a 
relatively unspecific staining method for senile plaques and neurofibrillary tangles 
(Wisniewski et al, 1989b), it may not differentiate between various types of 
dystrophic neurites, and thus it is likely that the semiquantitative assessment of 
neuritic plaques overestimates the density of AD-associated neuritic plaques i.e. those 
with tau-positive dystrophic neurites. Furthermore, the CERAD protocol does not use 
the other hallmark of AD, the neurofibrillary tangle, for defining the probability of 
AD. In contrast, the neurofibrillary tangles are considered as the main characteristics 
of AD in a recent staging method for AD: 
The Braak staging of neurofibrillary pathology (Braak et al, 1991) 
This staging scheme is based on the finding that the spread of neurofibrillary tangles 
to various brain regions follows a particular pattern during the progression of AD: the 
neurofibrillary tangles first appear in the transentorhinal cortex then the entorhinal 
cortex (transentorhinal stages I and II), thereafter they occupy the hippocampus 
(limbic stages III and IV), and eventually the association and primary cortex 
(isocortical stages V and VI). This staging method is reliable and reproducible (Nagy 
et al, 1997b). The cognitive status also correlates relatively well with the Braak stage 
(Grober et al, 1999; Gold et al, 2000; Jellinger 2000; Riley et al, 2002), although there 
is wide inter-individual variation in this correlation, and other factors, such as the 
density of cortical neuritic plaques, have an effect as well (Riley et al, 2002).  
Because the original Braak staging method required polyethylene glycol-
embedded brain samples, and analysis of 100?m thick sections stained with the 
Gallyas silver method, some less time-consuming and technically less demanding 
modifications have been developed (Nagy et al, 1998; Newell et al, 1999; Harding et 
al, 2000). 
The original protocol for the staging of neurofibrillary pathology (Braak et al, 
1991) suggests that only a sample from the visual cortex is necessary for the diagnosis 
of isocortical stages of AD. However, other isocortical areas may be affected by the 
neurofibrillary pathology before the visual association cortex is affected. Thus, there 
may be a need for an additional stage for these individuals. 
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The Braak staging of neurofibrillary pathology shares one of the problems 
related with the CERAD criteria (Mirra et al, 1991): it concentrates on only one of the 
hallmarks of AD. However, the NFTs are not specific to AD (Tolnay et al, 1999), 
although their distribution in various diseases varies (Ishizawa et al, 2002). To 
increase the specificity of the neuropathological criteria for AD the analysis of both 
hallmarks of AD were included in the next attempt: 
The National Institute and Reagan Institute (NIA-RI) criteria (The National Institute 
on Aging and Reagan Institute Working Group on Diagnostic Criteria for the 
Neuropathologic Assessment of Alzheimer's Disease 1997) 
These criteria contain some novel improvements over the previous ones: (a) the 
specificity of the diagnosis is increased by considering both neuritic plaques and 
NFTs, (b) both hallmarks are suggested to be evidence of a pathological process and 
not part of “normal or pathological aging” (Dickson 1997), and (c) as a consequence 
the age of an individual does not affect the interpretation. According to these criteria, 
there is a high likelihood that dementia is caused by AD if the patient has a CERAD 
score (Mirra et al, 1991) of “frequent” for neuritic plaques and Braak stage V or VI 
for neurofibrillary pathology (Braak et al, 1991). There is a moderate likelihood if the 
CERAD score is “moderate” and the Braak stage is III or IV, and there is a low 
likelihood if the CERAD score is “sparse” and the Braak stage is I or II.  
These criteria also have weaknesses. The inflexibility makes them difficult to 
use: there is no such linkage between the density of neuritic plaques and the Braak 
stages of neurofibrilary pathology as these criteria assume (Geddes et al, 1997; 
Knopman et al, 2003). As a result, a significant proportion of study subjects can not 
be categorised according to these criteria (Geddes et al, 1997). On the other hand, it is 
possible that part of this lack of correlation between the density of neuritic plaques 
and Braak stage is explained by problems in the definition of the “dystrophic 
neurites” (see above).  
An additional problem is that these criteria do not tell what to do with 
cognitively normal individuals with AD-type pathology. 
It is of note that while neurofibrillary tangles and senile plaques are the 
neuropathological characteristics of AD, dementia in individuals with AD is a result 
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of loss of functioning synapses (Terry et al, 1991). There is no linear correlation 
between the loss of synapses and other local pathology present (Minger et al, 2001). 
2.2. APOLIPOPROTEIN E 
2.2.1. The gene and its promoter 
The apolipoprotein E gene is located on the proximal long arm 
of human chromosome 19  (Olaisen et al, 1982; Das et al, 1985), and has four exons 
and three introns (Fig. 1)(Paik Y-K et al. 1985, Das HK et al. 1985). This gene 
encodes a mRNA of 1157 nucleotides, which consists of 61 un-translated nucleotides 
at the 5’ terminus, 54 nucleotides translating a signal peptide, 897 nucleotides coding 
for the mature protein, a UGA translation stop codon, and 142 un-translated 
nucleotides following the stop codon (McLean et al, 1984). Only exons 3 and 4 code 
for the mature protein. Two polymorphic sites within the APOE result in three 
common alleles ?2, ?3 and ?4 (Zannis et al, 1982a). In addition to these common 
polymorphisms, several mutations have been described (Table I). 
The APOE promoter contains multiple transcriptional enhancer and inhibitory 
elements, which are located upstream from the transcription start site and within the 
first and second introns (Paik et al, 1988; Smith et al, 1988; Simonet et al, 1993; Jo et 
al, 1995). Furthermore, in transgenic mice two regulatory units downstream from the 
APOE and the neighbouring APOCI genes appear to be involved in the liver-specific 
expression of the entire APOE/CI/CIV/CII gene cluster (of the long arm of the human 
chromosome 19), and two other downstream elements appear to control the apoE 
expression in macrophages and adipocytes (Simonet et al, 1990; Simonet et al, 1993; 
Allan et al, 1997; Shih et al, 2000). Thus, it is not surprising that this complicated 
regulatory system requires multiple transcription factors to activate or inhibit these 
elements (Chang et al, 1990; Berg et al, 1995; Jo et al, 1995; Garcia et al, 1996; 
Salero et al, 2001).
Three common polymorphisms upstream from the initiation site, an adenine to 
thymine substitution at site -491, cytosine to thymine at site -427, and thymine to 
guanine at site -219 (also called Th1/E47cs), affect the activity of the APOE promoter 
(Artiga et al, 1998a; Artiga et al, 1998b; Lambert et al, 1998b). Of these promoter 
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alleles, -219G, and APOE ?2 are in complete linkage disequilibrium (Lambert et al, 
1998a), and there also appears to be an association between the APOE ?4 allele, -219 
and another polymorphic site +113 in the first intron (Mui et al, 1996; Artiga et al, 
1998b; Lambert et al, 1998b). Both -219 and +113 sites are located within inhibitory 
regulatory elements in epithelial HeLa cell line (Smith et al, 1988), and the intronic 
inhibitory element also appears to be functional in astrocytes and in a hepatoma cell 
line (Garcia et al, 1996).  
   
Figure I.   Apolipoprotein E genea. The four thickened lines represent exons. 
Exon         I               II                         III                                 IV 
Nucleotide 1  44            805    870                         1963       2155         2738                                                        3597
5’  _?_______?____________???______???????????????__      3’
Number of            44         760      66             1092                  193          582                                  860                         
nucleotides 
in exons and 
introns 
a:   modified from Paik et al.1985 
2.2.2. Protein 
The apoE protein is a 299 amino acid glycoprotein of 34.1 kDa (Rall et al, 1982b). 
The structure of this protein varies as a result of genetic polymorphism (see above), 
post-translational modification with carbohydrate chains containing sialic acid 
(Zannis et al, 1981b) and, in diabetic subjects, by non-enzymatic glycosylation 
(Curtiss et al, 1985). The protein contains two major structural domains: (1) a 
compact and stabile globular amino-terminal domain (amino acid residues 20-165), 
and (2) a less stabile carboxy-terminal domain (amino acid residues 225-299) 
(Wetterau et al, 1988). These domains are connected to each other by a hinge region 
(amino acid residues 166-224) (Wetterau et al, 1988). The low density lipoprotein 
(LDL) receptor-binding region is between the residues 136-150 of the protein, where 
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multiple basic amino acids are present (Rall et al, 1982b; Weisgraber et al, 1983; 
Lalazar et al, 1988; Wilson et al, 1991). This same region, specifically residues 142-
147, is responsible for heparin binding (Weisgraber et al, 1986). There are other 
heparin binding regions within the apoE, but these are masked when it is bound to 
lipid (Weisgraber et al, 1986). The carboxy-terminal domain contains the major lipid-
binding region (Segrest et al, 1992). The amino acid residues 245-266 appear to be 
critical for binding to VLDL particles, while some binding to HDL occurs even 
without the carboxyl-terminal domain (Westerlund et al, 1993).  
ApoE molecules tend to self-associate as tetramers in aqueous solutions 
(Aggerbeck et al, 1988; Segrest et al, 1992). This tetramerization is mainly caused by 
residues 267-299 (Westerlund et al, 1993). However, apoE binds to lipids as a 
monomer (Yokoyama 1990), and this alters the secondary and tertiary structure (Roth 
et al, 1977; Chen et al, 1984b; Innerarity et al, 1984; Weisgraber et al, 1986; 
Weisgraber 1994). 
The three major apoE isoforms differ from each other by two cysteine-
arginine interchanges at positions 112 and 158 of the polypeptide chain. The apoE2 
isoform has cysteine and apoE4 arginine at both positions, apoE3 has cysteine at 
position 112 but arginine at 158 (Weisgraber et al, 1981; Rall et al, 1982b). The x-ray 
crystal structures of the amino-terminal domains of apoE3 and apoE4 show that only 
two side chains in apoE4 undergo conformational changes relative to their positions in 
apoE3 (Dong et al, 1994). The arginine at position 112 forms a salt bridge with the 
glutamic acid residue 109 (Dong et al, 1994), and pushes the arginine 61 outwards to 
a position in which it probably forms a salt bridge with glutamic acid 255 (Dong et al, 
1996). In apoE3 and apoE4 the arginine 158 forms salt bridges with the acidic side 
chains of glutamic acid 96 and aspartic acid 154, and as such may help to stabilize the 
conformation of the LDL receptor-binding region (Wilson et al, 1991). It is likely that 
the orientation of the receptor-binding region in apoE2 (with cysteine at position 158) 
is not optimal for binding with the LDL receptor (Innerarity et al, 1984; Wilson et al, 
1991; Weisgraber 1994). In addition, the carboxyl-terminal domain appears to affect 
the LDL binding-activity of apoE2 but not that of apoE3 (Dong et al, 1998).     
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2.2.3. Nomenclature 
The nomenclature of the various phenotypes of apoE protein is based on their 
isoelectric focusing positions and structures relative to the most common isoform, 
apoE3 (Zannis et al, 1982a; Rall et al, 1983; Weisgraber et al, 1984). However, this 
nomenclature does not include minor, sialylated isoforms. The sialylated isoforms 
apoE2s, E3s and E4s, which are more acidic than the asialylated isoforms apoE2, E3 
and E4, may occupy the E1 position or even more acidic positions on isoelectic 
focusing (Zannis et al, 1981b; Zannis et al, 1982a). To avoid confusion, the sialyl 
groups are detached from the mature protein by neuraminidase digestion during gel 
electrophoresis. Thus, in the nomenclature, the terms E1, E2, E3, E4 etc. describe the 
position of each asialylated apoE variant on isoelectric focusing, and the following 
code in parenthesis designates the names and sites of the substituted amino acids 
(Table I). For example, the designations of the three major isoforms (apoE2, apoE3 
and apoE4) which differ from each other by amino acid substitutions at two sites (112 
and 158) within the protein, involving cysteine-arginine interchanges (Weisgraber et 
al, 1981; Rall et al, 1982a; Rall et al, 1982b), should be: E2(Arg158?Cys), apoE3, 
and apoE4(Cys112?Arg). However, as a matter of convenience, these isoforms are 
referred to simply as apoE2, apoE3 and apoE4, and the other variants are referred to 
by the more descriptive designations.  
It is of note that the position on the isolectric focusing does not necessarily 
predict the amino acids at sites 112 and 158, and that genetic screening of these sites 
to detect the major alleles, ?2, ?3 or ?4, does not exclude the possibility of structural 
changes at other sites of the protein (Table I). In addition, the post-translational 
modification of apoE may affect the results of isoelectric focusing, particularly for 
diabetic individuals (Snowden et al, 1991).
2.2.4. Production   
The main source of plasma apoE is the liver, although it can be synthesized by 
virtually all other tissues (Wu et al, 1979; Zannis et al, 1982b; Blue et al, 1983; 
Driscoll et al, 1984; Reue et al, 1984; Newman et al, 1985; Zannis et al, 1985). In 
addition to the liver, particularly the brain, adrenal gland, kidney and gonads appear to 
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be active producers, whereas intestine, lung, muscle and fibrous tissue are relatively 
inactive synthesizers of apoE (Blue et al, 1983; Newman et al, 1985; Zannis et al, 
1985). Astrocytes appear to be the main producer within the brain (Boyles et al, 1984; 
Boyles et al, 1985; Murakami et al, 1988). However, neurons within the cerebral 
cortex, but not in the striatum or cerebellar cortex, are also able to express apoE (Xu 
et al, 1998). On the other hand, this appears to be species-specific, because rodent 
neurons do not express apoE (Xu et al, 1998). Ischaemia activates the neuronal 
production of apoE (Kazuko et al, 2003).  
The production of apoE in the liver is enhanced by dietary cholesterol (Lin-
Lee et al, 1981), and as a result the total plasma apoE increases following a 
cholesterol-rich diet (Mahley et al, 1977). Additionally, uptake of lipoproteins with an 
increase in the amount of intracellular free cholesterol rapidly induces macrophages to 
increase their production of apoE (Basu et al, 1982; Kayden et al, 1985; Mazzone et al, 
1987). Up to 12 % of the total protein secreted by macrophages can be apoE (Basu et 
al, 1983), which is secreted in the form of phospholipid/protein discs (Hamilton et al, 
1976; Marsh 1976; Basu et al, 1982).  Most of this is in sialylated form whereas most 
apoE in plasma is asialylated (81% versus 24%) (Zannis et al, 1981a; Basu et al, 1982; 
Zannis et al, 1982b; Zannis et al, 1984). Sialylation may be required for secretion 
(Zannis et al, 1984). 
2.2.5. Function 
The major functions of apolipoproteins include stabilization of the lipoprotein 
particles, redistribution of lipids among various tissues, and acting as cofactors for 
enzymes involved in lipoprotein metabolism (Franceschini 1996). ApoE probably acts 
as a stabilizing component in various lipoprotein particles (Mahley et al, 1975; 
Mahley et al, 1976; Guo et al, 1977; Roth et al, 1977). The redistribution of apoE to 
high density lipoprotein (HDL) particles increases their capability to accommodate 
cholesterol secreted from peripheral tissues (Basu et al, 1982; Mahley 1982). ApoE is 
also able to activate the lecithin-cholesterol acyltransferase (Chen et al, 1984a), which 
is needed to form cholesteryl esters from free cholesterol and acyl-lecithin. The 
cholesteryl esters form the core of HDL particles, which transport cholesterol from 
tissues or cells with elevated cholesterol to cells requiring cholesterol (Mahley 1982). 
However, possibly the most important function of apoE is to bind to the LDL receptor. 
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This results in more rapid and specific removal of lipoprotein particles rich in apoE 
than those richer in e.g. apolipoprotein A (Loeb et al, 1983). This binding between 
apoE and the LDL receptor appears to involve the direct 
ionic interaction of an array of oppositely charged residues (arginyl, lysyl, and 
possibly histidyl residues of apoE with aspartyl and glutamyl residues of the receptor) 
(Lalazar et al, 1988). The glycosylation of apoE lysyl residues may affect its LDL 
receptor-binding activity in diabetes (Curtiss et al, 1985). ApoE is also able to bind to 
the LDL-receptor-related protein (LRP)(Beisiegel et al, 1989), another receptor for 
lipoproteins and other ligands.
The structural differences between the three common result in variation in 
serum lipids. The interaction between the arginine 61 and glutamic acid 255 causes 
the preferential association of apoE4 with very low density lipoprotein (VLDL) 
instead of HDL as with apoE3 (Dong et al, 1996).  Individuals with the apoE4 have an 
increased risk of hypercholesterolemia (Uterman et al, 1984). Subjects with the apoE2 
seem to develop hypertriglyceridemia more often than subjects without this isoform 
(Uterman et al, 1984).  
2.2.6. ApoE and the nervous tissue 
The ability of apoE to increase the amount of cholesterol in lipoprotein particles and 
to bind effectively to lipoprotein receptors make it an important component in 
processes like nerve regeneration where rapid cholesterol transport is needed to 
support the membrane biogenesis of the growing axon. It has been hypothesized that 
the rate of nerve regeneration depends in part upon the efficiency of lipid transport 
from the local environment to the elongating axon and the myelin-forming cells 
(Boyles et al, 1989). Indeed, apoE supports and enhances the growth of neuronal 
processes (Ignatius et al, 1987; Handelman et al, 1992; Puttfarcken et al, 1997). In the 
central nervous system (CNS) apoE is the predominant apolipoprotein and its 
presence, either within lipoprotein particles or lipid-free, modulates the outgrowth of 
neuronal processes (Handelman et al, 1992; Strittmatter et al, 2002). In the CNS, the 
binding between apoE-containing lipoproteins and LRP is particularly important for 
the growth of neuronal processes (Narita et al, 1997). 
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A slightly surprising finding in transgenic mice is that apoE seems to be 
necessary for the maintenance of the integrity of the blood-brain barrier during aging 
(Mulder et al, 2001).
2.3. ALZHEIMER’S DISEASE AND APOLIPOPROTEIN E
2.3.1  Background 
Prior to the first scientific report linking the APOE ?4 allele with increased risk of AD 
(Strittmatter et al, 1993a), it was known that apoE is present in the hallmarks of AD, 
senile plaques (including diffuse plaques) and neurofibrillary tangles (Namba et al, 
1991), and in other types of amyloid as well (Wisnievski et al, 1992).   
2.3.2. Human association studies 
Clinical studies
According to clinical case-control and population-based studies, the APOE ?4 allele is 
significantly associated with early- (Mayeux et al, 1993; Okuizumi et al, 1994) and 
late-onset sporadic AD (Lucotte et al, 1993; Mayeux et al, 1993; Saunders et al, 
1993a; Saunders et al, 1993b; Kuusisto et al, 1994; Hong et al, 1996; Mak et al, 1996), 
familial early- (van Duijna et al, 1994) and late-onset AD (Anwar et al, 1993; Payami 
et al, 1993; Saunders et al, 1993b; Strittmatter et al, 1993a) and Alzheimer’s disease 
related with Down’s syndrome (Schupf et al, 1996), while APOE ?2 appears to have a 
protective effect (Talbot et al, 1994; West et al, 1994; Lambert et al, 1996; Schupf et 
al, 1996). The prevalence of AD may be lower in populations with low frequencies of 
carriers of the APOE ?4 allele (Hong et al, 1996; Pericak-Vance et al, 1996). There 
may be racial differences, Africans having a lower APOE ?4 allele associated risk of 
AD than Caucasians (Mayeux et al, 1993; Osuntokun et al, 1995; Farrer et al, 1997). 
The disease itself does not appear to be more aggressive in APOE ?4 carriers than in 
non-carriers (Corder et al, 1995; Holmes et al, 1996; Stern et al, 1997), although 
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gender may affect the association between mortality and the APOE ?4 allele in 
subjects with AD (Forno et al, 2002).  
In addition to the apparent increase in the life-time risk of AD (Seshadri et al, 
1995; Slooter et al, 1998), the APOE ?4 allele is associated with decreased age of 
onset when compared with other APOE alleleles (Payami et al, 1994; Roses et al, 
1994; Schupf et al, 1996; Khachaturian et al, 2004). The latter effect is pronounced 
particularly in individuals with two APOE ?4 alleles (Corder et al, 1993; Blacker et al, 
1997). It appears that APOE ?4 exerts its maximal effect in individuals in their 60s, 
and that this effect declines in older age groups, and may even disappear in very 
elderly individuals (Sobel et al, 1995; Blacker et al, 1997; Meyer et al, 1998). The 
effect of this allele on the onset of AD is stronger in women than in men (Payami et al, 
1994). This polymorphism may also affect the age of onset caused by mutations at 
chromosome 1, 14 and 21, but the confirmation of this association is problematic due 
to a limited number of such AD cases (Saunders et al, 1993a; Pastor et al, 2003).  
Neuropathological studies
The first neuropathological study on the association between the APOE ?4 allele and 
AD showed that APOE ?4 carriers with neuropathologically-confirmed AD had 
significantly more neuritic plaques and extracellular deposits of A? than non-carriers 
(Schmechel et al, 1993). This view has subsequently been challenged (Heinonen et al, 
1995; Soininen et al, 1995; Itoh et al, 1996; Landen et al, 1996; Chalmers et al, 2003). 
It should be noted, however, that the neuropathological diagnosis of AD itself 
depends on the presence of a sufficient minimal density of neocortical senile plaques, 
which decreases the possible variation in the number or density of senile plaques 
between individuals with AD and, as a result, decreases the possibility of detecting 
differences between subgroups. In addition, age and gender may affect the strength of 
the association between the APOE ?4 allele and Alzheimer-type pathology 
(Ghebremedhin et al, 2001). Regardless, the APOE ?4 allele is strongly associated 
with neuropathologically-confirmed AD (Zubenko et al, 1994). While elderly 
individuals with the APOE ?4 allele have increased AD-type neuropathology, subjects 
with the apoE ?2/?3 genotype have less dense deposition of A?  than subjects with the 
apoE ?3/?3 genotype (Lippa et al, 1997).  
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It has been suggested that although A? peptide aggregations may occur 
without apoE, this protein is necessary for the stabilization of the A? aggregations 
within amyloid fibrils (Wisniewski et al, 1992; Kida et al, 1994; Cho et al, 2001). As 
the APOE ?4 allele is associated with increased A? load, this allele should be able to 
facilitate the deposition of this peptide. However, it does not look as though the 
cortical soluble apoE level is affected by the apoE genotype (Pirttilä et al, 1996). 
Additionally, in individuals with the apoE ?2/?4 genotype equal amounts of both apoE 
forms appear to be present in A? aggregations (Cho et al, 2001), suggesting that once 
these aggregations are formed both apoE variants attach equally to the growing senile 
plaque. However, the initial deposition of A? occurs at an earlier age in APOE ?4
carriers than in non-carriers (Morishima-Kawashima et al, 2000). In fact, the cortical 
insoluble A? 42 level appears to be above the baseline in approximately 90% of non-
demented APOE ?4 carriers aged 50 years or more (Morishima-Kawashima et al, 
2000; Yamaguchi et al, 2001). Although a long time-period with continuously 
increasing deposition of cortical A? peptide precedes the onset of dementia in AD, the 
early initial deposition of A? in APOE ?4 carriers may be enough to explain the 
earlier onset of clinical AD in these subjects (Yamaguchi et al, 2001).       
 In addition to the earlier deposition of A?, the first neurofibrillary tangles also 
occur earlier in the cerebral cortex of APOE ?4 carriers than in those of non-carriers 
(Ghebremedehin et al, 1998). This may explain why APOE ?4 carriers reach high 
Braak stages earlier than non-carriers (Ohm et al, 1999) and the higher density of 
neurofibrilary tangles in the neocortex (Nagy et al, 1995b). The neocortical tau load is 
also higher in AD patients with the APOE ?4 allele (Thaker et al, 2003). 
In conclusion, it is likely that the APOE ?4 allele is associated with the clinical 
manifestations of AD primarily through its association with the AD pathology in the 
aging brain (Bennett et al, 2003). In contrast, it does not seem likely that APOE ?4 is 
associated with problems in the development of the CNS or in cognitive function in 
the early years of life (Gaynor et al, 2003; Puttonen et al, 2003).  
ApoE4 variant associated with Alzheimer’s disease
An apoE variant resembling the apoE4, apoE4(Leu28?Pro, Cys112?Arg), is 
associated with AD (Kamboh et al, 1999; Scacchi et al, 2003). Although it appears to 
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increase the risk of AD even more than the “wild-type” apoE4, the difference between 
these two apoE4 variants is not significant (Kamboh et al, 1999; Scacchi et al, 2003). 
On the other hand, only 2-3% of all apoE4 carriers appear to have the mutant form, 
which results in relatively small numbers in comparisons (Kamboh et al, 1999; Orth et 
al, 1999; Scacchi et al, 2003). In addition to AD, this apoE4 variant is associated with 
increased risk of coronary artery disease, and lower plasma total cholesterol level 
when compared with the normal apoE4, and much less mutant apoE4 is accumulated 
in HDL particles (Orth et al, 1999). Thus, the Leu28?Pro substitution may result in a 
change in the lipid-binding characteristics. The normal apoE4 itself has a decreased 
tendency to accumulate in HDL particles when compared with apoE3 due to the 
interaction between the arginine 61 and glutamic acid 255 (Dong et al, 1996). 
Because proline, a known helix-broker, at position 28 probably destroys at least part 
of the first amphipathic helix within the N-terminal domain, and this position is 
relatively near position 61 in the three-dimensional structure (Weisgraber 1994), this 
mutation may have an effect on the interaction between the arginine 61 and glutamic 
acid 255 in apoE4, or cause a new interaction between the N-terminal and C-terminal 
domains.
ApoE promoter and Alzheimer’s disease 
Three polymorphic sites, -491, -427 and -219 (see also section 3.1. Gene and its 
promoter) in the APOE promoter region have been suggested to modify the risk of 
AD in case-control studies (Artiga et al, 1998a; Bullido et al, 1998; Lambert et al, 
1998a; Lambert et al, 1998b). A recent meta-analysis on six independent samples 
(totalling 1723 patients with AD and 1926 controls) confirmed the association 
between AD and the polymorphisms at sites -491 and -219 (Lambert et al, 2002). It 
has been suggested that the varying production of apoE, and particularly that of apoE4, 
might affect the risk of AD (Artiga et al, 1998a; Lambert et al, 1998a). Indeed, in 
heterozygous individuals (carriers of genotypes apoE ?3/?4 or apoE ?2/?4) with AD 
the production of apoE4 was higher than in heterozygous individuals without AD 
(Lambert et al, 1998a). However, there was no unequivocal evidence that this 
production correlated with either the -491 or -219 sites (Lambert et al, 1998a). 
Furthermore, in almost all (99%) individuals the expression of apoE4 was lower than 
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the expression of the other apoE variant, irrespective of the presence or absence of 
AD or the polymorphisms in the APOE promoter (Lambert et al, 1998a). Thus, these 
results suggest that other factors have a more significant effect on the production of 
apoE4 than the known polymorphic sites of the APOE promoter.
2.3.3.  Biochemistry 
ApoE avidly binds and increases the fibril formation of A? (Strittmatter et al, 1993a; 
Wisnievski et al, 1993; Castano et al, 1995). The C-terminal domain of apoE, and 
particularly the segment between amino acids 244-272, is required for this binding 
(Strittmatter et al, 1993b). However, the results of studies concerning isoform-specific 
binding activity have been inconsistent: it seems that purified, monomeric apoE4 
binds faster toA? than does apoE3 (Strittmatter et al, 1993b), but when native (non-
monomeric, lipid-associated) apoE is used, apoE2 and apoE3 are more efficient in this 
binding than is apoE4 (LaDu et al, 1994; LaDu et al, 1995; Zhou et al, 1996; Yang et 
al, 1997). ApoE protects neurons from the toxic effects of A? probably via interaction 
with lipoprotein receptors, but again the results concerning isoform-specific actions 
have been inconsistent – even between studies executed by the same reseach group 
(Puttfarcken et al, 1997; Jordan et al, 1998). Because the native form of apoE is more 
likely to occur in physiological conditions than is the purified form, these results and 
the finding that the deposition of A? in the cerebral cortex is increased in APOE ?4
carriers suggest that the clearance of A? from the extracellular space is affected in 
APOE ?4 carriers. 
 In addition to differences between the binding activities of various apoE 
isoforms to A?, there is also analogous variation between the binding activities of 
apoE variants to tau and microtubule-associated protein (MAP) 2c: the binding 
activity of apoE3 is significantly stronger than that of apoE4 (Huang et al, 1994; 
Roses 1994). This difference in binding capacity may have an effect on the stability of 
these two structural variants.     
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2.3.4.  Hypotheses of pathogenesis 
(1) The association between AD and the APOE ?4 allele is a result of linkage 
disequilibrium between APOE and a nearby pathogenetic gene locus. This is 
unlikely, because in spite of attempts to test this possibility no competing 
nearby genetic loci have been found.  
(2) The binding of oxygenated, lipid-free apoE4 to A? is much more rapid and 
stronger than the binding of apoE3 to A? (Strittmatter et al, 1993b). This may 
result in accumulation of A? in APOE ?4 carriers, and due to the neurotoxicity 
of A?, eventually lead to the death of neurons (Kamboh 1995). This 
accumulation may also occur within neurons as a result of endocytosis of the 
apoE-A? complexes after they have bound to cell surface receptors (LaFerla et 
al, 1997; Cataldo et al, 2000). Because apoE2 has significantly reduced 
binding activity to receptors of the LDL-family, the intraneuronal 
accumulation of A? is less likely to occur in carriers of the APOE ?2 allele 
(LaFerla et al, 1997). 
  This hypothesis is challenged by the fact that the native apoE4 is less 
active in binding to A? than are the apoE2 and apoE3 (Yang et al, 1997).  
(3)  The strong binding of apoE4 to A? probably results in decreased 
concentration of functionally active apoE. Because apoE is a neuroprotective 
protein, the decrease in its concentration may also affect its neuroprotective 
capacity (Kamboh 1995). Again, inconsistent results concerning the isoform-
specific binding activity of apoE to A? challenge this hypothesis. 
(4) Native apoE2 and apoE3 bind A? much more avidly than does native apoE4 
(Yang et al, 1997). Thus, apoE4 may be associated with impaired clearance of 
A? from the extracellular space due to altered apoE-?? interaction (Kamboh 
1995; Yang et al, 1997). If this hypothesis is true, the concentration of A? in 
the CSF does not reflect the probably high local levels of soluble A? in the 
cerebral cortex, because high A? levels in CSF decrease the risk of dementia 
in non-demented elderly individuals (Skoog et al, 2003). 
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(5) Whatever the reason for the accumulation of A?, the tendency of apoE to bind 
A? and the stability of the amyloid fibrils may lead to chronic activation of the 
cell surface receptors of neighbouring neurons by amyloid-bound apoE (Cho 
et al, 2001). This chronic receptor activation may be harmful to neurons.  
(6) The binding of apoE3 (and possibly of apoE2) to tau and microtubule-
associated protein 2c may protect them from phosphorylation, thus slowing 
the formation of neurofibrillary tangles (Huang et al, 1994; Roses 1994). In 
contrast, the poor ability of apoE4 to bind to tau may lead to abnormal 
phosphorylation, and eventually neurofibrillary tangles will form (Roses 1994; 
Kamboh 1995). ApoE3 also binds another microtubule-associated protein, 
MAP2, more avidly than does apoE4 (Huang et al, 1994).  
This hypothesis is challenged by a finding that a subset of senile 
dementia, “senile dementia with tangles”, characterized by abundant 
neurofibrillary tangles within the temporal cortex and lack of senile plaques, is 
associated with the APOE ?2 allele, and the frequency of carriers of the apoE 
?4 allele is lower than in controls (Ikeda et al, 1997). 
(7) Because apoE4 is not as effective in supporting the growth of neuronal 
processes as is apoE3, the plasticity of the brain may be poorer in individuals 
with the APOE ?4 allele (Poirier et al, 1995). One would expect that any 
degenerative process in the brain would be enhanced in individuals with the ?4
allele, if this hypothesis would be true. The relatively specific association 
between the APOE ?4 allele and AD does not support this hypothesis.  
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3. This study  
3.1. Aims of the study 
The purpose of this study was to examine the effect of the APOE ?4 allele on the 
occurrence of dementia and AD-type neuropathological changes in a Finnish, very 
elderly population. Very old individuals are most suitable for studies on dementia and 
AD because both are common in these subjects. In addition, population-based 
neuropathological studies on very elderly individuals are uncommon. Furthermore, 
the Finnish population is suitable for studies on the effect of the APOE ?4 allele due 
to the high frequency of carriers in this population.   
The questions to be answered by this study were: 
I Is the APOE ?4 allele associated with AD-type neuropathological changes i.e. 
cortical amyloid ?-protein load and neurofibrillary tangles? 
II  Does the APOE ?4 allele have an effect on the prevalence of dementia or 
neuropathologically verified Alzheimer’s disease? (III) 
III Is the incidence of dementia affected by the APOE ?4 allele? (IV) 
IV Is the severity of Alzheimer’s disease-type changes modified by a genetic 
polymorphism at the APOE promoter locus? (II) 
3.2. Materials and methods
3.2.1. The population 
The Vantaa 85+ Study population includes 601 persons, all at least 85 years of age, 
who were living in the town of Vantaa (Southern Finland) on April 1, 1991.  Of these, 
553 (92%) participated in the baseline study in 1991. Eleven of the remaining 48 
subjects refused, one could not be contacted, and 36 had died prior to examination. 
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The 553 individuals underwent a structured general and neurological examination 
performed by a neurologist and a registered nurse. Genotyping at the APOE locus was 
possible in 532 of these subjects. The survivors were re-examined in 1994, 1996, 
1999 and 2001. One non-demented genotyped subject who moved to another town 
soon after the baseline study, and could not be contacted later, was excluded from the 
follow-up cohort. See also the flow chart in Figure II. 
3.2.2. Clinical examination and diagnosis of dementia 
Cognitive functions were assessed by the Mini-Mental State Examination (Folstein et 
al, 1975), the Short Portable Mental Status Questionnaire (Pfeiffer 1975), and the 
Clinical Dementia Rating (Hughes et al, 1982). Functional abilities were assessed by 
the Activities of Daily Living and Instrumental Activities of Daily Living Scale (Katz 
et al, 1963; Lawton et al, 1969). Subjects were considered demented if they fulfilled 
the criteria in the Diagnostic and Statistical Manual of Mental Disorders, (American 
Psychiatric Association 1987) (DSM IIIR), and the duration of the dementia 
symptoms was at least three months. Individual items of the criteria were assessed and 
recorded separately. Assessments were based on data obtained from interviews, 
examinations, previous health and social work records and tests of cognitive function 
and functional capacity. The diagnosis of dementia was made by two of the authors 
together (Dr Raimo Sulkava together with Drs Auli Verkkoniemi, Sari Rastas, 
Annamaija Sutela or Petteri Viramo). Furthermore, health and social work records 
were used to identify new cases of dementia among those who were non-demented in 
the baseline study in 1991 or in the follow-up studies, but who died more than one 
year after their last follow-up examination. Also the cases found in this way fulfilled 
the individual items of the DSM-IIIR criteria (American Psychiatric Association 
1987).
   The onset of a dementing disorder in a person diagnosed to be demented in 
this study is the time of the first disturbing cognitive symptoms (usually memory 
problems) reported by the relatives or health care staff, or seen from the health 
records.
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Figure II. Flow chart: The Vantaa 85+ Study population.    
Total 1.4.1991
601
 Clinically examined
Total   APOE known 
 553      532 
Died before 
examination
36
Refused
11
Could not be 
contacted 
1
Autopsy
15
Non-demented
Total APOE known 
 338      328 
Demented
Total APOE known 
 215       203 
Died by 1.4.2001
Total APOE known 
 215       203 
Autopsy
Total APOE known 
128       122 
Remained
non-demented 
Total APOE known
231       223 
Could not be 
contacted 
Total APOE known 
   1          1 
Incident dementia 
Total APOE known 
 106      105 
Died by 1.4.2001 
Total APOE known 
 218             211 
   Died by 1.4.2001
Total APOE known 
  93        92 
Autopsy 
Total APOE known 
 102         99 
Autopsy
Total APOE known 
  61        60 
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3.2.3. Genotyping 
DNA was extracted from peripheral blood cells or tissue samples according to  
tandard procedures. The genotyping of the different polymorphisms was performed 
using the primers and conditions summarized in Table 2. 
Table 2. Primers and restriction enzymes used for the amplification of APOE
polymorphisms. 
________________________________________________________________
Gene   Primers      Assay 
__________________________________________________________________
APOEa  TCCAAGGAGCTGCAGGCGGCGCA  CfoI
   ACAGAATTCGCCCCGGCCTGGTACACTGCCA 
APOE promoter -491 TGTTGGCCAGGCTGGTTTTAA   DraI
   CCTCCTTTCCTGACCCTGTCC 
APOE promoter -219 AGAATGGAGGAGGGTGCCTG   BstNI
   ACTCAAGGATCCCAGACTTG 
APOE intron 1 (IE1) TGAGAAGCGCAGTCGGGGGCA   NIaIV 
   AGGTCCAGTCCCCTGCTGCT 
___________________________________________________________________
a: For apolipoprotein E genotyping two methods, DNA minisequencing 
(Syvänen et al, 1993) and DNA amplification by polymerase chain reaction 
followed by restriction enzyme digestion with HhaI (Hixson et al, 1990), were 
independently used in two laboratories (Department of Medicine, University 
of Helsinki, Finland, and Mayo Clinic, Jacksonville, Florida, respectively) 
with identical results. In the case of 16 individuals, only one method was used 
owing to limited amount of DNA available. 
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3.2.4. Neuropathological examination 
Sampling
A total of 306 individuals were autopsied during the time period 1.4.1991- 1.4.2001. 
The brains of the autopsied individuals were fixed in phosphate-buffered 4% 
formaldehyde solution for at least two weeks. After fixation, tissue blocks were 
obtained from the middle frontal, superior temporal, and middle temporal gyri and 
inferior parietal lobule, according to the protocol for the diagnosis of AD outlined by 
the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) (Mirra et al, 
1991). Care was exercised during sampling of these tissue blocks that the cutting axis 
was perpendicular to the surface of the gyrus and the full thickness of cortex was 
present. These tissue blocks were embedded in paraffin. In addition, tissue samples 
for staging of neurofibrillary changes (Braak et al, 1991) were obtained from the 
entorhinal cortex at the level of the mamillary bodies, from the hippocampus at the 
level of the lateral geniculate body, and from the occipital lobe, so that the striate area, 
parastriate field and peristriate region were all represented in the same tissue block. 
These tissue blocks were embedded in polyethylene glycol 1000. 
Quantitation of the A? load
The paraffin-embedded tissue blocks were cut at a thickness of 8 ?m for staining with 
methenamine silver to detect the diffuse and neuritic senile plaques. To estimate the 
A? load in cerebral neocortex, the fraction of the cortical area covered by 
methenamine silver-stained plaques was quantified. Contiguous cortical microscopic 
fields, extending from the pial surface to the white matter, were examined at a 
magnification of 100X with a square microscopical graticule, 1.25 mm in width, 
along a line perpendicular to the pial surface. The graticule consists of 10 horizontal 
and 10 vertical lines with 100 intersections. All intersections that overlay a 
methenamine silver-positive plaque were counted. In every specimen at least 7 
(maximum 10) cortical columns (width 1.25 mm) were examined from the pial 
surface to the white matter, and the fraction of cortex covered by plaques was 
determined by dividing the number of intersections overlying a methenamine silver-
 39
positive plaque by the total number of cortical intersections. The average fraction of 
cortex covered by methenamine silver-positive plaques was calculated for all 
specimens (from the middle frontal, superior temporal, and middle temporal gyri and 
inferior parietal lobule) from each subject to minimize the possible effect of variations 
in the A? load in different regions of the brain. The final value (expressed as 
percentage) provided an estimate of the A? load in the cerebral cortex. 
Counting of neurofibrillary tangles
The neurofibrillary tangles were counted in the same modified Bielschowsky-stained 
slides that were used for scoring the neuritic senile plaques. In each of the four 
samples (the middle frontal, superior temporal, and middle temporal gyri and inferior 
parietal lobule), the neurofibrillary tangles were counted in five random columns, 
width 0.5 mm, extending from the pial surface to the white matter, using a grid of 0.5 
x 0.5 mm at 200X magnification. The average number of tangles per column was used 
in the statistical analysis. 
Scoring of the neuritic senile plaques
The paraffin-embedded tissue blocks were cut at a thickness of 10 ?m for staining 
with a modified Bielschowsky method for neuritic plaques. The entire cortical area of 
each sample (the middle frontal, superior temporal, and middle temporal gyri and 
inferior parietal lobule) was screened at a magnification of 100X with a square 
microscopical graticule, to find an area of 1mm2 with the maximum density of 
neuritic plaques. This area was then scored according to the CERAD protocol for the 
diagnosis of AD (Mirra et al, 1991), without knowledge of the clinical diagnosis, 
apoE genotype or the stage of neurofibrillary pathology.    
Staging of the neurofibrillary pathology 
The tissue blocks embedded in polyethylene glycol were cut at a thickness of 80 ?m
for free-floating staining with the Gallyas silver method for neurofibrillary pathology.  
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Braak staging was performed as described earlier (Braak et al, 1991) without 
knowledge of the clinical diagnosis, apoE genotype or the neuritic plaque score. 
Diagnosis of neuropathological AD in this study
Two neuropathological criteria for AD were used in this study. Individuals with 
“probable” or “definite” AD according to the CERAD criteria (Mirra et al, 1991) were 
categorised as AD patients in some experiments, while modified NIA-RI criteria were 
applied in others. The latter criteria define an AD patient as an individual with a 
“moderate” or “frequent” CERAD score for neuritic plaques (Mirra et al, 1991) and 
Braak stage IV, V or VI for neurofibrillary pathology (Braak et al, 1991). 
Correspondingly, the “No neuropathological AD” group was defined either as 
“normal with respect to AD” according to the CERAD criteria (Mirra et al, 1991), or 
as individuals with no neuritic plaques or a “sparse” CERAD score (Mirra et al, 1991) 
and Braak stage (Braak et al, 1991) no more than II according to the modified NIA-RI 
criteria. The reason for using the modified NIA-RI criteria is explained in the section: 
“Prevalence of Alzheimer’s disease and the APOE ?4 allele (publication II)”.  
3.2.5. Statistical Analyses 
The differences between the groups were examined using ?2 and Fisher’s exact tests 
for categorical variables and the independent sample t test for continuous variables 
that follow a normal distribution. The correlation between genotype and cortical A?
load was assessed by the Kruskall-Wallis non-parametric test. The association of the 
genotypes and other factors with continuous variables was analyzed using multiple 
regression. Logistic regression was used to examine the association between variants 
and the disease, with adjustment for potential confounding factors. The statistical 
analyses mentioned above were performed using the SPSS and STATA programs. 
Hardy-Weinberg equilibrium was examined by the HWSIM program. Linkage 
disequilibrium between loci was determined by the Estimated Haplotype Frequencies 
program (Xie et al, 1993). 
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3.3. Approval for the study 
This study was approved by the Ethics Committee of the Health Centre of the City of 
Vantaa. The use of the health and social work records and death certificates was 
approved by the Finnish Health and Social Ministry. Blood sample collections were 
performed after obtaining informed consents from the subjects or their relatives. The 
collection of the tissue samples at autopsy, and their use for research, was approved 
by the National Authority for Medicolegal Affairs. Written consent for autopsy were 
obtained from the nearest relatives. 
.
3.4. Results and discussion 
APOE genotype and neocortical Alzheimer-type changes (publication I) 
Only 17 (18%) of the 92 subjects had no detectable A? in their neocortical samples. 
The presence of A? was strongly associated with the presence of the ?3 and ?4 alleles: 
staining was positive in 31 (94%) of 33 subjects with at least one ?4 allele and in 39 
(83%) of 47 subjects who were homozygous for the ?3 allele, but only in 5 (42%) of 
12 with the ?2/?2 or ?2/?3 genotype. 
 The A? load was higher in subjects with dementia than in those without, but 
varied in both groups in a similar way according to the apoE genotype. When all 92 
individuals were analyzed together, the mean A? load was significantly (p<0.001) 
higher in the 33 APOE ?4 carriers than in the 59 non-carriers. In addition, individuals 
with the ?2/?3 genotype had significantly (p<0.02) lower A? load than subjects with 
the ?3/?3 genotype. 
 The mean number of neurofibrillary tangles was significantly (p<0.001) 
higher in subjects with at least one ?4 allele than in subjects with no ?4 allele. 
 Gender or age did not significantly affect the A? load or number of 
neurofibrillary tangles within the genotype groups except for subjects with the apoE 
?2/?3 genotype in whom there was a correlation between age and number of 
neurofibrillary tangles (p=0.01). 
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 Many studies have tried to show an apoE genotype-related effect on AD-type 
pathology by examining subjects with AD. These studies have led to contradictory 
results (Schmechel et al, 1993; Heinonen et al, 1995; Soininen et al, 1995; Itoh et al, 
1996; Landen et al, 1996; Chalmers et al, 2003), probably due to the selection of 
subjects – all had a relatively severe AD-type pathology by definition. In contrast, our 
study involved very elderly individuals from a prospectively clinically examined 
population irrespective of their cognitive functions.    
 Over 80% of these individuals had detectable A? depositions (methenamine 
silver-positive senile plaques) in their neocortex. This deposition was associated with 
the apoE genotype both in demented and non-demented individuals. This result also 
suggests that the number of individuals with preclinical AD is higher among the 
APOE ?4 carriers than in non-carriers. 
The number of neurofibrillary tangles was also higher in APOE ?4 carriers 
than in non-carriers. Thus, both hallmarks of AD, senile plaques and neurofibrillary 
tangles, were more common in individuals with the ?4 allele. 
Prevalence of Alzheimer’s disease and the APOE ?4 allele (publication II)  
Gender did not affect the prevalence of dementia: 35% of men and 39% of women 
were demented. The prevalence of clinically-diagnosed vascular dementia (VaD) was 
19%, AD 16%, and other types of dementia 3%.  
We used modified NIA-RI criteria ( see the section: “Diagnosis of 
neuropathological AD in this study”) for the neuropathological diagnosis of AD. 
These criteria were used for two reasons. First, there was no significant difference in 
the proportion of subjects with moderate or frequent plaques (CERAD scores for 
probable or definite AD in this age group) between the no-dementia group and the 
clinical AD group when the proportions were analyzed separately in APOE ?4 carriers 
and non-carriers. In contrast, individuals who fulfilled the modified consensus criteria 
for neuropathologic diagnosis of AD were significantly (p=0.007) more common in 
the clinical AD group than in the no-dementia group.  
The second reason was that it was not possible to follow the original NIA-RI 
recommendations because in our very elderly study population, the scores of neuritic 
plaques according to the CERAD protocol (Mirra et al, 1991) and the stages of 
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neurofibrillary pathology (Braak et al, 1991) did not match as suggested in these 
recommendations. For example, subjects with a moderate neuritic plaque score 
according to the CERAD criteria could have any stage of neurofibrillary pathology.  
When modified NIA-RI criteria were used only 33 (45%) of the 74 individuals 
with neuropathologic AD were in the correct group according to the clinical diagnosis; 
41 (55%) were either in the no-dementia group or in the VaD or other dementia group. 
Eighteen (35%) of those with clinical AD did not fulfill the neuropathologic criteria 
for AD used in this study. It should be noted that, especially in population-based 
studies with limited diagnostic facilities, there is a possibility of misdiagnosis. For 
example, the presence of ischaemic lesions may result in the incorrect exclusion of 
demented subjects from the AD group (Nolan et al, 1998; Holmes et al, 1999). On the 
other hand, subjects with dementia with Lewy bodies and argyrophilic grains disease 
(Victoroff et al, 1995; Klatka et al, 1996; Braak et al, 1998), both common in elderly 
people, may be erroneously included among AD patients. In two other population-
based studies comprising younger age groups and applying the CERAD 
neuropathologic criteria on a small fragment of the population, the Cache County 
Study and the Liverpool MRC-ALPHA Study, the clinical non-AD dementia groups 
included 60% to 80% neuropathologically defined AD cases, equivalent to our results 
(Breitner et al, 1999). 
Some of the demented subjects in our study survived many years after the day 
of point prevalence. In these cases, AD might have developed during the interval 
between the diagnosis of dementia and death, the primary cause of dementia being 
other than AD. However, in general the demented individuals died relatively soon 
after the baseline study: the mean interval between the baseline study and death was 
2.9 years, and the median 2.2 years. 
 Neuropathologic AD was significantly more common among APOE ?4
carriers than in noncarriers in the clinical AD (p=0.001) and clinical VaD or other 
dementia (p=0.001) groups. The association between APOE ?4 and neuropathological 
AD (OR 6.9) was stronger than the association between APOE ?4 and dementia (OR 
2.9) or clinical AD (OR 2.5).  
 The estimated prevalence of neuropathologic AD was 33% for all subjects 
aged 85 years or more. In subjects with APOE ?4, the prevalence of neuropathologic 
AD was more than three times the prevalence for subjects without APOE ?4 (20% vs 
63%). Age group (85-89 years vs 90 years and over) did not significantly affect this 
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relationship. Because we have used neuropathologic criteria for the diagnosis of AD 
irrespective of the clinical dementia status, it is difficult to compare our results with 
other studies using purely clinical criteria for AD diagnosis. The reported prevalence 
of AD in people aged 85 years or more has varied between 13% and 47% in clinical 
population-based studies (Evans et al, 1989; Fratiglioni et al, 1991; Bachman et al, 
1992; Skoog et al, 1993; Ott et al, 1995), but the lack of neuropathologic confirmation 
of the diagnosis of AD in these studies may weaken the accuracy of their estimates. 
Regardless, when neuropathological criteria are used, a previous proposal “that – 
regardless of APOE genotype – more than half of the population will not develop AD 
by age 100” (Meyer et al, 1998) does not seem to be valid in our population. 
Incidence of dementia, occurrence of neuropathological AD, and the APOE ?4 allele
(publication III)  
Of the 328 non-demented individuals at baseline, 73 (22 %) were men and 255 (78 %) 
were women. Twentysix (36 %) of the men and 43 (17 %) of the women were APOE 
?4 allele carriers. Thus, significantly larger proportion of men than of women had the 
APOE ?4 allele (p<0.001). 
16-34% of the survivors died each year after the baseline study (Figure I). 
Because of the high mortality rate, only 60% (154 of 255) of those aged 85-89 years 
at the baseline study could be clinically examined at least twice. The corresponding 
figures for non-demented subjects who reached ages 90-94 years and 95 years or 
more during the follow-up were 63% (97 of 155 individuals) and 43% (12 of 28 
individuals; an additional nine individuals reached the age of 95 years between the 
last two clinical follow-up examinations and were excluded from this calculation). 
According to the survival curve (not shown) the time-interval between the follow-up 
examinations should have been 1.2 years for non-demented individuals aged 85-89 
years, 1.4 years for those aged 90-94 years and 1.6 years for those aged 95 years or 
more to allow at least two clinical examinations for 80% of participants. 
By April 1st, 2001 105 (32 %) of the 328 originally non-demented individuals 
had been diagnosed with dementia. Of these diagnoses, 88 were based on the results 
of the follow-up examinations and medical records, and 17 on the medical records 
only. The mean time from the last clinical examination (i.e. the baseline or follow-up 
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examination) to death was significantly longer in these 17 individuals than in those 
who were non-demented at death (2.57 ± 1.65 years vs. 1.29 ± 1.09 years, p<0.001).     
    The incidence of dementia in all individuals aged 85 years or more was 69 per 
1000 person-years (95% confidence interval from 56 to 85) if only the results of the 
follow-up examinations were used. However, inclusion of the additional 17 cases with 
incident dementia based on the medical records only, resulted in over 20 % increase 
in the incidence of dementia. In this case the incidence of dementia for all individuals 
aged 85 years or more was 85 per 1000 person-years (95% confidence interval 70 to 
101). Gender, age group (85-89 years vs 90 years and more) or the presence of APOE
?4 did not significantly affect the incidence of dementia.     
    Altogether, 303 of the 328 individuals died ? 211 were non-demented and 92 
had incident dementia at death ? during the ten year follow-up. 99 (47%) of the 211 
deceased who were non-demented at death and 60 (65%) of 92 subjects with incident 
dementia were autopsied. Twenty (20%) of the 99 who were not diagnosed with 
dementia and 26 (43%) of the 60 individuals with incident dementia fulfilled the 
neuropathological criteria for AD. It is of note, however, that none of these 159 
autopsied subjects were totally free of neurofibrillary tangles or neuritic plaques.  
Because the long time-period between the last clinical examination and death 
appeared to cause discrepancy between the results of the follow-up examinations and 
medical records (see above), we performed a logistic regression analysis to test 
whether this time-period was associated with the occurrence of neuropathological AD 
in non-demented individuals. Nine of the 17 individuals whose dementia diagnosis 
was based on the medical records only were autopsied. If these 9 autopsied 
“discrepant” incident dementia cases were included in the analysis as non-demented 
individuals, the time from the last clinical examination was almost (p=0.053) 
significantly positively correlated with the neuropathological AD in the non-demented 
individuals. However, this trend disappeared, if these cases were excluded from the 
analysis. Gender was not associated with neuropathological AD in non-demented 
individuals, but age at death appeared to have an effect.  
The APOE ?4 allele was highly significantly (p=0.002) associated with 
neuropathological AD in non-demented individuals. APOE ?4 carriers were also 
significantly (p=0.031) more common among the subjects with incident dementia and 
neuropathological AD than among non-demented individuals without 
neuropathological AD (8 of 26 vs. 9 of 79). The APOE ?3/?4 genotype was also 
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significantly (p=0.003) associated with neuropathological AD when compared with 
with the ?2/?3 or ?3/?3 genotypes in the autopsied individuals. In addition, the 
proportion of carriers of the ?3/?4 genotype in the “No neuropathological AD” group 
was only 3% (1 of 29), while the corresponding figure was 21% (22 of 104) for those 
with the ?3/?3 genotype, and 32% (7 of 22) for  those with the ?2/?3 genotype (p = 
0.02 for difference between carriers of the ?3/?4 genotype and others).  Surprisingly, 
while dementia was significantly associated with neuropathological AD in individuals 
without APOE ?4 (12 neuropathological AD cases in 82 non-demented subjects vs 18 
in 44 demented subjects; p<0.001), no such association was present in APOE ?4
carriers (8 neuropathological AD cases in 17 non-demented subjects vs 8 in 16 
demented subjects).
The incidence of dementia increases exponentially with age, at least up to the age of 
90 years (Jorm et al, 1998). According to a meta-analysis of incidence of dementia in 
Europe, the incidence in individuals aged 85-89 years is 48.6 per 1000 person-years 
and in subjects aged 90 years or more 70.2 per 1000 person-years (Fratiglioni et al, 
2000). These figures are similar to our follow-up data. Our incidence figures were 
higher, however, when the information based on the medical records was also 
considered: the incidence of dementia in subjects aged 85-89 years was 83 per 1000 
person-years, and in subjects aged 90 years or more 87 per 1000 person-years. The 
APOE ?4 carrier status, age group or gender did not significantly affect the incidence 
of dementia. However, at the baseline there was a significant difference between the 
non-demented men and women in the proportions of the APOE ?4 carriers (36% vs 17 
%, p<0.001). Interestingly, the proportion of APOE ?4 carriers among the non-
demented men in this study was almost exactly the same as in Finnish children 
(Lehtimäki et al, 1990). These findings suggest that the proportion of APOE ?4
carriers among non-demented women has decreased before the age of 85 years but 
this has not happened in men. 
The high mortality of these very elderly individuals resulted in a rapid 
decrease in the number of subjects. Thus, a significant proportion of subjects were 
lost between follow-up examinations as a result of the relatively long follow-up 
periods in our study. Only 43-63% of non-demented individuals in various age groups 
could be examined at least twice. The problem related with long follow-up periods 
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appears to be common in these kinds of studies. In other recent population-based 
studies on the incidence of dementia the follow-up periods have varied between 1 and 
4.1 years (mean 2.5 years) (Aronson et al, 1991; Bachman et al, 1993; Letenneur et al, 
1994; Paykel et al, 1994; Gussekloo et al, 1995; Aevarsson et al, 1996; Clarke et al, 
1996; Fratiglioni et al, 1997; Ott et al, 1998; Copeland et al, 1999; Ganguli et al, 2000; 
Riedel-Heller et al, 2001). Two or three year follow-up periods cause underestimation 
of the incidence figures for dementia in very elderly individuals, if the medical 
records are not used to diagnose unnoticed dementia in individuals who have died 
during the follow-up period. However, the quality of information in medical records 
varies, and in particular the exclusion of the possibility of dementia may not be 
reliable. Thus, even when medical records are used, as in our study, the results may 
underestimate the true incidence of dementia. 
Neuropathological analysis of the AD-type pathology was possible in almost 
half of those who were non-demented at the time of death, and in almost two thirds of 
subjects with incident dementia who died during the ten year follow-up. According to 
the neuropathological criteria used in this study, 43% of those with incident dementia 
had AD. However, neuropathological AD was also common among those who were 
non-demented at the time of death: 20% of these individuals fulfilled the 
neuropathological criteria for AD. Thus, our results are in concordance with other 
studies, which show that non-demented elderly individuals may have prominent AD-
type pathology, probably as a result of a preclinical phase of AD (Hulette et al, 1998; 
Schmitt et al, 2000). On the other hand, if this preclinical phase was extended to cover 
all kinds of AD-type pathology (i.e. any density of neocortical neuritic plaques or 
cortical neurofibrillary tangles), then all these 159 autopsied individuals who were 
non-demented at baseline would have been affected by AD.  
In spite of the lack of significant association between the APOE ?4 allele and 
incident dementia there was a significant association between this allele and 
neuropathological AD. Furthermore, the APOE ?3/?4 genotype was significantly 
underrepresented among individuals whose cognition was unlikely to be affected by 
the existing AD-type pathology. Because APOE ?4 is associated with dementia 
mainly through its association with the pathological hallmarks of AD (Bennett et al, 
2003), it is likely that other diseases or degenerative processes, which are not 
associated with the APOE ?4 allele (Gomez-Isla et al, 1996; Ikeda et al, 1997; 
Ghebremedhin et al, 1998), had caused dementia in many of these very elderly 
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individuals, and diluted the effect of neuropathological AD on the incidence of 
dementia. The lack of association between neuropathological AD and dementia in 
APOE ?4 carriers may have the same explanation. In this small group of individuals 
with relatively extensive AD-type pathology additional pathology may be more 
important. Regardless, it seems that the clinical dementia diagnosis gives only a rough 
idea about the overall pathology within the very elderly brain.  
It has been shown that most non-demented APOE ?4 carriers show 
accumulation of the amyloid ?42-peptide in their cerebral cortex after 50 years of age 
(Morishima-Kawashima et al, 2000), and that Braak stage I of neurofibrillary 
pathology occurs significantly more commonly in young adults (mean age 38 years) 
with APOE ?4  than without (Ghebremedehin et al, 1998). This early formation of the 
first AD-type changes eventually leads to an earlier appearance of clinical AD 
(Corder et al, 1993). In this study, approximately 50% of APOE ?4 allele carriers had 
neuropathological AD. All these very elderly individuals had been non-demented at 
the baseline. Our previous report showed that almost 80% of the autopsied APOE ?4
carriers who were demented at baseline, had neuropathological AD (see publication 
II). Thus, the majority of very elderly APOE ?4 carriers had neuropathological AD at 
death. However, although on average the AD-type pathology was more severe in the 
APOE ?4 carriers, all autopsied non-carriers who were non-demented at baseline also 
showed at least some AD-type changes. If the minimal AD-type changes in young and 
middle-aged APOE ?4 carriers (see above) are accepted as the first signs of AD, it is 
logical to assume that the same lesions in these very elderly non-carriers represent the 
beginning of the same disease process. Thus, it seems likely that all these subjects had 
a potential to develop AD, but the timing and/or pace of the process is modified by 
genetic and possibly environmental factors.  
Is the extent of Alzheimer’s disease-type changes modified by a genetic polymorphism 
at the apoE promoter locus? (publication IV). 
    
The APOE promoter polymorphism had a significant association with A? load in 
individuals with the apoE ?3/?3 genotype. Individuals with the -219T/-219T genotype 
had the lowest (0.4%), while those with the -219G/-219G genotype had the highest 
(2.0%) median level of amyloid deposition in the cerebral cortex (p=0.005 for the 
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difference between genotypes). The -219G allele was also associated with AD 
according to both neuropathological criteria used (CERAD and modified NIA-RI). 
There was noo significant association between the A? deposition, or 
neuropathological AD according to the CERAD criteria, and polymorphisms at the  
-491 or +113 (IE1) sites. However, when modified NIA-RI criteria were used, the 
polymorphism at the +113 (IE1) site appeared to have a significant effect on the risk 
of neuropathologically-defined AD (p = 0.005). 
Polymorphisms at the APOE promoter locus have been associated with AD. Our 
study suggested that the neocortical A? load is also affected by one of these 
polymorphisms. However, results of various studies have been contradictory (Mui et 
al, 1996; Artiga et al, 1998b; Blacker et al, 1998; Bullido et al, 1998; Lambert et al, 
1998b; Liao et al, 1998; Wavrant-De Vrieze et al, 1999). This probably means that 
even if these polymorphisms truly affect the risk of AD or A? deposition, their effect 
is not comparable to that of the APOE polymorphism, and multiple other genetic and 
environmental factors can modify their possible effect. In addition, the linkage 
disequilibrium between the promoter and enhancer region and the APOE alleles 
makes the interpretation problematic (see section “the gene and its promoter”). 
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4. Concluding remarks
The main results of this study were: 
I The APOE ?4 allele was significantly associated with the neocortical A? load 
in both demented and non-demented individuals. In addition, the 
neurofibrillary pathology was more severe and extensive in subjects with the 
APOE ?4 allele.  
II The APOE ?4 was significantly associated with the prevalence but not with the 
incidence of dementia. However, there was a significant association between 
APOE ?4 and neuropathologically-defined AD in individuals aged 85 years or 
more, irrespective of the clinical diagnosis of dementia. Thus, it was not 
clinically possible to detect all subjects with extensive AD-type changes, 
particularly not in the carriers of the APOE ?4 allele. Although our study 
protocol did not allow us to clinically diagnose individuals with MCI, it is 
likely that AD-related MCI is more common among APOE ?4 carriers than 
among non-carriers.  
III AD-type changes to some extent were almost invariably present within the 
brains of these very elderly individuals. This suggests that each of them had 
the potential to develop AD, but that there was a wide inter-individual and (at 
least) genetically modified variation in the timing and/or pace of this process. 
It also seems likely that other, non-APOE ?4-dependent neurodegenerative 
processes are common and cause dementia in these very elderly individuals. 
IV It is possible that polymorphisms within the APOE promoter region also 
modulate the neocortical A? load and the risk of AD, but this effect is weaker 
than the effect of the APOE ?4 allele. 
V The current neuropathological criteria for AD need further development. 
Possibly, strengthening of the importance of neuropathological parameters 
with good correlations with dementia – i.e. hyperphosphorylated tau-
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pathology in the form of neurites and NFT – might improve the specificity. On 
the other hand, more detailed analysis of the senile plaque type and possibly 
some modifications in the analysis of the stage of the neurofibrillary pathology 
might be worthwhile in research settings.  
The weaknesses of this study include the autopsy frequency, which was 
approximately 40% for the non-demented and 60% for the demented 
subpopulation. In this type of study it is not possible to totally exclude a 
selection bias. The very old age group in this study makes comparisons 
problematic with studies focusing on younger individuals problematic. The 
lack of other population-based neuropathological studies, which obviously is 
the strength of this study, also makes comparisons problematic, because it 
seems that the clinical diagnosis of dementia may not correlate well with AD-
type neuropathology in this age group. The neuropathological findings of all 
individuals were used for the analysis, because the whole population was the 
target of this study. However, the staging of the neurofibrillary pathology is 
problematic in subjects whose medial temporal region is destroyed by another 
neurodegenerative disease. This is particularly true with individuals suffering 
from hippocampal sclerosis. On one hand, this disorder is relatively rare, and 
may cause problems only in subjects with early stages of neurofibrillary 
pathology – neocortical stages of neurofibrillary pathology can be identified 
also in these individuals. On the other hand, it is also possible that other 
primary neurodegenerative diseases modulate the AD-type neuropathology 
irrespective of the apoE genotype, which may affect the results. However, a 
rigorous selection based on neuropathological findings would have made it 
impossible to perform a population-based study, due to the common co-
occurrence of multiple pathologies in these very elderly individuals. 
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